Blood test may help tailor chemo for colorectal cancer patients
NCT ID NCT07562659
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with stage I or low-risk stage II colorectal cancer who have a positive ctDNA blood test one month after surgery, indicating a higher risk of recurrence. Researchers will assign different chemotherapy regimens based on ctDNA results to see if this personalized approach can clear the cancer DNA from the blood and improve survival. The trial aims to find better ways to prevent cancer from coming back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Capecitabine, FOLFOX, CAPOX, FOLFIRI, CAPEIRI (chemotherapy drugs)
What this could lead to
If successful, this approach could help doctors choose the right chemotherapy for each patient, potentially reducing the chance of cancer coming back.
What could go wrong
This is a small, early-phase trial with only 80 participants, so results may not apply to everyone. Chemotherapy can cause side effects like fatigue, nausea, and nerve damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
Contact